Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer Patients With Personalized Therapy (SUBITO) - an International Randomized Phase III Trial

NCT02810743 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT02810743
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02810743 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer Patients With Personalized Therapy (SUBITO) - an International Randomized Phase III Trial
Lead sponsor
The Netherlands Cancer Institute
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 25, 2017
Completion date
December 1, 2033
Enrollment
174 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer